Abstract
Clopidogrel, an antiplatelet agent, prevents platelet aggregation by inhibiting the adenosine disphosphate (ADP) P2Y12 receptor, which is located on the platelet surface. Although dual antiplatelet therapy appears to be efficient, a considerable number of patients continue to experience adverse cardiovascular events, such as stent thrombosis. The percentage of low response to antiplatelet therapy varies from 4% to 30% of patients depending on the cut-off values. In addition, several factors such as poor absorption, drug-to-drug interactions, inadequate dosing, elevated body mass index, insulin resistance and the nature of acute coronary syndromes have been implicated in low clopidogrel response. Recently, studies have focused on the role of genetic polymorphisms encoding enzymes that participate in clopidogrel hepatic metabolism or receptors involved in intestinal absorption and ADP induced platelet aggregation, which may affect the percentage of platelet inhibition after clopidogrel administration. The management of clopidogrel resistance remains a controversial issue and additional studies are required to evaluate the safety and efficacy of increased loading of clopidogrel or replacement with other new antiplatelet agents such as prasugrel.
Keywords: Clopidogrel resistance, cytochrome P450, gene polymorphisms, platelets, thrombus, Clopidogrel, atherosclerosis, adenosine disphosphate, atherosclerotic disease, multifactorial pattern, cytochrome, carbon monoxide, enzymes, phospholipids, detoxification, coagulation, body mass index, polymorphisms, platelet, healthy Caucasians, coronary artery disease, erythromycin, antiplatelet therapy, percentile distribution, platelet function analyzer (PFA), vasodilator, phosphoprotein
Current Medicinal Chemistry
Title: The Role of the Cytochrome P450 Polymorphisms in Clopidogrel Efficacy and Clinical Utility
Volume: 18 Issue: 3
Author(s): D. Tousoulis, G. Siasos, M. Zaromytidou, N. Papageorgiou, E. Stefanadi, E. Oikonomou and C. Stefanadis
Affiliation:
Keywords: Clopidogrel resistance, cytochrome P450, gene polymorphisms, platelets, thrombus, Clopidogrel, atherosclerosis, adenosine disphosphate, atherosclerotic disease, multifactorial pattern, cytochrome, carbon monoxide, enzymes, phospholipids, detoxification, coagulation, body mass index, polymorphisms, platelet, healthy Caucasians, coronary artery disease, erythromycin, antiplatelet therapy, percentile distribution, platelet function analyzer (PFA), vasodilator, phosphoprotein
Abstract: Clopidogrel, an antiplatelet agent, prevents platelet aggregation by inhibiting the adenosine disphosphate (ADP) P2Y12 receptor, which is located on the platelet surface. Although dual antiplatelet therapy appears to be efficient, a considerable number of patients continue to experience adverse cardiovascular events, such as stent thrombosis. The percentage of low response to antiplatelet therapy varies from 4% to 30% of patients depending on the cut-off values. In addition, several factors such as poor absorption, drug-to-drug interactions, inadequate dosing, elevated body mass index, insulin resistance and the nature of acute coronary syndromes have been implicated in low clopidogrel response. Recently, studies have focused on the role of genetic polymorphisms encoding enzymes that participate in clopidogrel hepatic metabolism or receptors involved in intestinal absorption and ADP induced platelet aggregation, which may affect the percentage of platelet inhibition after clopidogrel administration. The management of clopidogrel resistance remains a controversial issue and additional studies are required to evaluate the safety and efficacy of increased loading of clopidogrel or replacement with other new antiplatelet agents such as prasugrel.
Export Options
About this article
Cite this article as:
Tousoulis D., Siasos G., Zaromytidou M., Papageorgiou N., Stefanadi E., Oikonomou E. and Stefanadis C., The Role of the Cytochrome P450 Polymorphisms in Clopidogrel Efficacy and Clinical Utility, Current Medicinal Chemistry 2011; 18 (3) . https://dx.doi.org/10.2174/092986711794839151
DOI https://dx.doi.org/10.2174/092986711794839151 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Childhood Alopecia Areata: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Thiazolidinediones and Cardiovascular Risk — A Question of Balance
Current Cardiology Reviews Uterine Function: From Normal to Polycystic Ovarian Syndrome Alterations
Current Medicinal Chemistry Update on Pharmacologic Approaches to Prevent Thromboembolism in Atrial Fibrillation: Are Thrombin and Factor Xa Inhibitors the Ultimate Answer?
Current Vascular Pharmacology Remediation of Cellular Hypoxic Damage by Pharmacological Agents
Current Pharmaceutical Design Effect of Electromagnetic Radiations on Neurodegenerative Diseases- Technological Revolution as a Curse in Disguise
CNS & Neurological Disorders - Drug Targets Current Therapeutic Concepts in Peripartum Cardiomyopathy
Current Pharmaceutical Design Epoxyeicosatrienoic Acids as a Therapeutic Target for Nephropathy Associated with Diabetes and Hypertension
Current Hypertension Reviews The Effects of Smoking Cessation on Diabetes Mellitus Patients
Current Diabetes Reviews Metabolic Programming Nowadays (or Perhaps Now and then?)
Current Nutrition & Food Science Generic Clopidogrel Besylate in the Secondary Prevention of Atherothrombotic Events: A 6-month Follow-up of a Randomised Clinical Trial
Current Vascular Pharmacology Mass Spectrometric Quantification of Urinary Netrin-1 Protein in Renal Transplant Recipients
Current Proteomics Exploring the Cardio-metabolic Relevance of T-cadherin: A Pleiotropic Adiponectin Receptor
Endocrine, Metabolic & Immune Disorders - Drug Targets Evaluating Drug Safety in Children and Adolescents with Bipolar Disorder
Current Drug Safety Editorial [Hot Topic: New Concepts of Angiotensin Receptor Blocker (ARB) in Atherosclerosis: ARB as a Metabolic-Improving Agent (Guest Editor: Minako Yamaoka-Tojo)]
Current Vascular Pharmacology Genetics of Gestational Diabetes Mellitus
Current Medicinal Chemistry Blood Pressure and White Matter Lesions in Patients with Vascular Disease: The SMART-MR Study
Current Neurovascular Research Medicinal Agents and Metabolic Syndrome
Current Medicinal Chemistry Delivery of Peptides Via the Oral Route: Diabetes Treatment by Peptide-Loaded Nanoparticles
Current Pharmaceutical Design Multiple Pregnancies After ART and How to Minimize their Occurrence
Current Women`s Health Reviews